Ian L P Beales1,2, Leanne Dearman3, Inna Vardi3, Yoon Loke4. 1. Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, NR4 7UZ, UK. i.beales@uea.ac.uk. 2. School of Medicine, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK. i.beales@uea.ac.uk. 3. Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, NR4 7UZ, UK. 4. School of Medicine, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK.
Abstract
BACKGROUND: Use of statins has been associated with a reduced incidence of esophageal adenocarcinoma in population-based studies. However there are few studies examining statin use and the development of Barrett's esophagus. AIM: The purpose of this study was to examine the association between statin use and the presence of Barrett's esophagus in patients having their first gastroscopy. METHODS: We have performed a case-control study comparing statin use between patients with, and without, an incident diagnosis of non-dysplastic Barrett's esophagus. Male Barrett's cases (134) were compared to 268 male age-matched controls in each of two control groups (erosive gastro-esophageal reflux and dyspepsia without significant upper gastrointestinal disease). Risk factor and drug exposure were established using standardised interviews. Logistic regression was used to compare statin exposure and correct for confounding factors. We performed a meta-analysis pooling our results with three other case-control studies. RESULTS: Regular statin use was associated with a significantly lower incidence of Barrett's esophagus compared to the combined control groups [adjusted OR 0.62 (95 % confidence intervals 0.37-0.93)]. This effect was more marked in combined statin plus aspirin users [adjusted OR 0.43 (95 % CI 0.21-0.89)]. The inverse association between statin or statin plus aspirin use and risk of Barrett's was significantly greater with longer duration of use. Meta-analysis of pooled data (1098 Barrett's, 2085 controls) showed that statin use was significantly associated with a reduced risk of Barrett's esophagus [pooled adjusted OR 0.63 (95 % CI 0.51-0.77)]. CONCLUSIONS: Statin use is associated with a reduced incidence of a new diagnosis of Barrett's esophagus.
BACKGROUND: Use of statins has been associated with a reduced incidence of esophageal adenocarcinoma in population-based studies. However there are few studies examining statin use and the development of Barrett's esophagus. AIM: The purpose of this study was to examine the association between statin use and the presence of Barrett's esophagus in patients having their first gastroscopy. METHODS: We have performed a case-control study comparing statin use between patients with, and without, an incident diagnosis of non-dysplastic Barrett's esophagus. Male Barrett's cases (134) were compared to 268 male age-matched controls in each of two control groups (erosive gastro-esophageal reflux and dyspepsia without significant upper gastrointestinal disease). Risk factor and drug exposure were established using standardised interviews. Logistic regression was used to compare statin exposure and correct for confounding factors. We performed a meta-analysis pooling our results with three other case-control studies. RESULTS: Regular statin use was associated with a significantly lower incidence of Barrett's esophagus compared to the combined control groups [adjusted OR 0.62 (95 % confidence intervals 0.37-0.93)]. This effect was more marked in combined statin plus aspirin users [adjusted OR 0.43 (95 % CI 0.21-0.89)]. The inverse association between statin or statin plus aspirin use and risk of Barrett's was significantly greater with longer duration of use. Meta-analysis of pooled data (1098 Barrett's, 2085 controls) showed that statin use was significantly associated with a reduced risk of Barrett's esophagus [pooled adjusted OR 0.63 (95 % CI 0.51-0.77)]. CONCLUSIONS: Statin use is associated with a reduced incidence of a new diagnosis of Barrett's esophagus.
Authors: Yu Fang; Xiaoxin Chen; Manisha Bajpai; Amit Verma; Kiron M Das; Rhonda F Souza; Katherine S Garman; Claire L Donohoe; Naoimh J O'Farrell; John V Reynolds; Katerina Dvorak Journal: Ann N Y Acad Sci Date: 2013-10 Impact factor: 5.691
Authors: Xiaocheng Wu; Vivien W Chen; Patricia A Andrews; Bernardo Ruiz; Pelayo Correa Journal: Cancer Causes Control Date: 2007-04-04 Impact factor: 2.506
Authors: Florine Kastelein; Manon C W Spaander; Katharina Biermann; Ewout W Steyerberg; Ernst J Kuipers; Marco J Bruno Journal: Gastroenterology Date: 2011-08-28 Impact factor: 22.682
Authors: Jeffrey Molendijk; Thi-My-Tam Nguyen; Ian Brown; Ahmed Mohamed; Yenkai Lim; Johanna Barclay; Mark P Hodson; Thomas P Hennessy; Lutz Krause; Mark Morrison; Michelle M Hill Journal: Biomolecules Date: 2020-05-16